Active Ingredient History

  • Now
Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown.   NCATS

  • SMILES: NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
  • Mol. Mass: 305.159
  • ALogP: 0.6
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1,3-disulfamoyl-4,5-dichlorobenzene | 1,3-disulfamyl-4,5-dichlorobenzene | 3,4-dichloro-5-sulfamylbenzenesulfonamide | 4,5-dichloro-1,3-benzenedisulfonamide | 4,5-dichloro-1,3-disulfamoylbenzene | 4,5-dichlorobenzene-1,3-disulfonamide | 4,5-dichloro-benzene-1,3-disulfonic acid diamide | 4,5-dichloro-m-benzenedisulfonamide | daranide | dichlofenamide | dichlorophenamide | dichlorphenamide | diclofenamid | diclofenamida | diclofenamide | diclofenamidum | glaucol | oratrol


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue